Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Ask Therapept

Plain-English answers grounded in primary literature

Every answer is composed deterministically from verified scientific records, clinical trials, FDA labeling, and analytical lab data. No language model in the loop, zero synthetic hallucinations, and clear distinctions between human trials and animal models.

Popular questions with verified answers:
Medical Boundary:Therapept is an open-access scientific reference and educational catalog, not a clinic or medical provider. Answers are composed deterministically from verified database records, clinical trials, and FDA labeling. We never provide personal diagnoses, medical treatments, or individualized dosing instructions.
Question AnsweredDeterministic Attributed Record

what is BPC-157 being studied for

1

Verified Source-Derived Information

Preclinical Animal Evidence & Regulatory Safety Alerts·Reviewed: 2026-09-24
  • ✓Preclinical mechanism: Upregulates VEGF and early growth response protein-1 in rodent tendon/gastrointestinal injury models.
  • ✓Clinical gap: Zero completed, peer-reviewed Phase 3 human clinical trials published in PubMed/MEDLINE.
  • ✓Regulatory restriction: Placed on FDA Compounding Category 2 (significant safety concerns); prohibited by WADA under Category S0.
Attributed Sources:
2

Educational Explanation & Context

The Plain-English Summary

BPC-157 is a 15-amino-acid synthetic fragment of a stomach protein researched in rodent models for tendon, ligament, and stomach ulcer healing. Crucially, BPC-157 has ZERO completed Phase 3 randomized human clinical trials.

Technical Mechanism & Details

In laboratory rats and mice, BPC-157 upregulates vascular endothelial growth factor (VEGF) and activates focal adhesion kinase (FAK)-paxillin pathways to stimulate capillary sprouting (angiogenesis) and fibroblast migration. While widely promoted in online fitness and biohacking communities, the FDA placed BPC-157 on Category 2 bulk compounding restrictions due to immunogenicity concerns, and WADA bans it under Category S0.

BPC-157 (Body Protection Compound 157) attracts enormous public curiosity because rodent studies show rapid soft-tissue recovery, reduced tendon inflammation, and accelerated gastric ulcer repair.

However, there is an immense evidence gap: nearly all published data comes from animal models (predominantly a single research group in Croatia), with no completed, peer-reviewed human Phase 3 clinical trials verifying efficacy, human dosage, or long-term safety.

3

Unknown / Not Available & Regulatory Boundaries

Preclinical rodent evidence cannot be extrapolated to human clinical efficacy or safety. Uncontrolled human self-administration carries unknown immunogenicity and purity risks.

Explicit Limitations & File Gaps:
  • •Zero completed Phase 3 human randomized controlled trials in orthopedic or gastrointestinal medicine.
  • •FDA Category 2 bulk compounding restriction in the United States.
  • •WADA banned substance under category S0 (Unapproved Substances).

Helpful Follow-Up Questions

Related Guides & References on Therapept

How Ask Therapept Works: Deterministic Transparency

  • •Zero AI Hallucinations: Every answer is synthesized directly from verified database records, published peer-reviewed studies, FDA drug labels, and analytical chemistry testing guides. There is no generative language model fabricating unverified claims.
  • •Source Tier Transparency:Claims follow Therapept’s Level 1–5 evidence hierarchy — official FDA labeling, peer-reviewed research, editorial synthesis, and separated community signals.
  • •Honest Limits: Therapept will not provide personal medical advice, recommend unapproved dosages, or turn forum gossip into facts. When information is unstudied or restricted, Therapept states so clearly.